Genmab — April 2020

[kkjoel]

Ja, lahn, lad os nu se....

[Solsen]

Man mener at have noget fornuftigt og afslutter med at sige vi høres ved sidst i maj ???

[Solsen]

Jeg kunne godt forestille mig, at plasma har helbredt mange og er kørt godt ind inden. Vi er måske heldige med en effekt på 60-80%

[Bulder]

Solsen, du skal skelne mellem NIAID-studiet og Gileads egne 2 studier, hvor vi vil få resultarer sidst i maj. Det andet Gilead-studie (moderat): "shortly". Niaid: "upcoming)

[Bulder]

Rettelse: Moderat: sidst i maj. Svær covid19 "shortly"

[Bulder]

I øvrigt ville det være bedst, hvis vi fører covid19 diskussion i covid19-chatten, når nu Helge har gjort sig den ulejlighed at oprette den.

[Solsen]

Ok

[Helge_LarsenPI-redaktør]

Tak Bulder.

[E_L]

i think i might have the one to blame lol

[E_L]

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab https://www.nature.com/articles/s41375-020-0840-y

[Sukkeralf]

We already have seen Farydak (panobinostat) - a pan HDAC inihibitor approved for MM. I dont think Novartis ever made trials with daratumumab even though panobinostat also upregulates CD38. Tox issues with HDAC are heavy if I remember correctly

[E_L]

do you happen to know if JNJ owns such an inhibitor?

[Sukkeralf]

but maybe its a different story with a selective HDAC6 inhibitor - so lets give ricolinostat a warm welcome in combination with daratumumab :-)'

[Sukkeralf]

I dont think so

[E_L]

[Sukkeralf]

Its seems like Celgene bought Acetylon Pharmaceuticals and outsourced ricolinostat to Regenacy Pharmaceuticals

[Sukkeralf]

So I guess we will not see anything from that - nice papers but no commercial value

[GeorgeBest]

Webinar https://twitter.com/genmab/status/1255519832063258624?s=21

[E_L]

ASCO titels up https://meetinglibrary.asco.org/results/Epcoritamab ?meetingView=2020 ASCO Virtual Scientific Program&page=1

[E_L]

Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or...